

Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X^1 , R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

